VENUSREM — Venus Remedies Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSuper Stock

Annual income statement for Venus Remedies, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,481	5,986	5,555	6,014	6,479
Cost of Revenue
Gross Profit	2,073	2,132	2,123	2,301	2,693
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5,062	5,696	5,271	5,678	5,970
Operating Profit	419	290	284	337	509
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	486	364	379	446	718
Provision for Income Taxes
Net Income After Taxes	618	407	266	285	453
Net Income Before Extraordinary Items
Net Income	618	407	266	285	453
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	618	407	266	285	453
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	37.7	30.9	19.9	21.3	29.2